Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1992-12-31
|
pubmed:abstractText |
The disposition of the enantiomers of MK-571 (MK-0679 and L-668,018) following single i.v. doses of MK-571 (L-660,711) was studied in a three way cross-over study in 12 healthy male volunteers. Each volunteer received 75 mg, 300 mg and 600 mg i.v. doses of MK-571 at weekly intervals. The disposition of both enantiomers appeared dose-dependent, since the AUC increased disproportionately faster than the dose. The dose dependency was much more pronounced for L-668,018: its AUC increased 6-fold from the 75 to the 300 mg dose, 16-fold from 75 to 600 mg and 2.7 fold from 300 to 600 mg. For MK-0679, the corresponding increases in AUC were 4.8-, 11-, and 2.3 fold. Regardless of dose, the elimination of L-668,018 was more rapid than that of MK-0679. The disposition of MK-0679 needs to be investigated independently to detect any potential influence of L-668,018 on its disposition.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0031-6970
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
43
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
431-3
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1451726-Adult,
pubmed-meshheading:1451726-Dose-Response Relationship, Drug,
pubmed-meshheading:1451726-Humans,
pubmed-meshheading:1451726-Infusions, Intravenous,
pubmed-meshheading:1451726-Male,
pubmed-meshheading:1451726-Propionates,
pubmed-meshheading:1451726-Quinolines,
pubmed-meshheading:1451726-Reference Values,
pubmed-meshheading:1451726-SRS-A
|
pubmed:year |
1992
|
pubmed:articleTitle |
Dose-dependent kinetics of the enantiomers of MK-571, and LTD4-receptor antagonist.
|
pubmed:affiliation |
Department of Pharmacology, School of Medicine, University of Leuven, Belgium.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|